Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829383 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
A Phase 2 study of Unresectable Hepatocellular Carcinoma, sponsored by Howard S Hochster.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT04829383: Active Phase 2 study of Unresectable Hepatocellular Carcinoma, sponsored by Howard S Hochster.
NCT04829383 is a Phase 2 study of Unresectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Howard S Hochster. The registered enrollment target is 50 participants, below the 82-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04829383, a Phase 2 study of Unresectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Howard S Hochster.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
Primary Outcome
Number of participants with grade 3-5 treatment-related adverse event reported by CTCAE v5 term and grade
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
Study Locations (7)
Illinois
- University of Illinois Cancer Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- New York University Clinical Cancer Center - New York
Texas
- DHR Health Institute for Research and Development - Edinburg
Wisconsin
- Univeristy of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
What the registry record for NCT04829383 still lists
NCT04829383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 82-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04829383 lists 7 locations in 7 states (Illinois, Indiana, Nebraska).
Frequently Asked Questions
What is clinical trial NCT04829383 about?
NCT04829383 is a clinical study titled "A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma". This will be a nonrandomized, single arm feasibility study with the primary goal of evaluating the safety profile of the combination of atezolizumab and bevacizumab in patients with advanced/metastatic HCC with Child-Pugh B7 and B8 liver disease who have received no prior systemic therapy.
What is the current status of trial NCT04829383?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-03-22. Estimated completion is 2025-10.
What conditions does trial NCT04829383 study?
This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT04829383?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT04829383?
This trial is sponsored by Howard S Hochster, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829383 being conducted?
This trial has 7 study locations across Illinois, Indiana, Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04829383's enrollment target sits among peer trials
50 6th of 12 higher than 7 of 12 other Unresectable Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unresectable Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
RECRUITING · Phase 2
-
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
COMPLETED · Phase 2
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI